A team of senior clinician and basic scientists leads our ambitious research program to understand the causes of eye disease, improve the diagnosis of treatment of disease, prevent vision loss and restore sight.
Associate Professor Penny Allen
Associate Professor Penny Allen leads the bionic eye research at CERA. Her team has developed a next-generation bionic eye implant which is now in trial and has been implanted in four patients.
Associate Professor Allen is also working on new trials for patients with poor vision due to inherited disease.
Associate Professor Michael Coote
MBBS, FRANZCO, GAICD
Associate Professor Michael Coote is a Principal Investigator at CERA and the Clinical Director of Ophthalmology at the Royal Victorian Eye and Ear Hospital.
A/Prof Coote has been researching surgical solutions for glaucoma for over 20 years and is a consultant to the Glaucoma Clinic at Hospital.
Professor Mark Daniell
MB BS, MS, FRANZCO, FRACS
Professor Mark Daniell is the Head of the Corneal Unit at the Royal Victorian Eye and Ear Hospital and Professor at CERA and the University of Melbourne.
His main research interests are in cornea and external disease and stem cell surgery, as well as surgery of the cornea and lens.
Dr Thomas Edwards
MBBS, PhD, FRANZCO
Dr Thomas Edwards’ research looks at the potential of gene therapy to cure inherited retinal diseases.
His research aims to establish the infrastructure and knowledge base necessary to develop treatments that may halt or partially reverse some inherited causes of blindness.
Dr Jennifer Fan Gaskin
MBChB, MD, FRANZCO
Dr Jennifer Fan Gaskin leads ocular fibrosis research at CERA and is a Consultant Ophthalmologist at the Royal Victorian Eye and Ear Hospital (RVEEH).
Dr Fan Gaskin’s current research focus is on developing an effective and safe method of controlling postoperative scarring for glaucoma operations, preventing blindness.
Professor Robyn Guymer AM
MBBS, PhD, FRANZCO, FAAHMS
Professor Robyn Guymer is a clinician scientist who leads a team of researchers primarily investigating age-related macular degeneration (AMD).
She is currently investigating new strategies for treating early stages of AMD with a nanosecond laser and is working to identify novel imaging and functional biomarkers and surrogate endpoints to improve the feasibility of conducting early intervention trials.
Professor Mingguang He
MD, PhD, FRANZCO
Professor Mingguang He is a global expert in vision-related clinical and epidemiologic research. He led several important population-based studies in China, including the first glaucoma survey and a large-scale twin study in China.
His research interests include clinical and epidemiological research, randomized clinical trials, twin studies and imaging technology. His current research priority is big data and precision medicine.
Associate Professor Wilson Heriot
Associate Professor Wilson is conducting a translational project to bring his method of improved retinal detachment repair into routine clinical care.
This project was awarded a United States Government Congressionally Awarded Grant of $1.48 million and is being conducted in collaboration with researchers in the Department of Optometry and Vision Sciences, University of Melbourne.
Professor Alex Hewitt
BMedSci (Hons), MBBS, PhD
Professor Alex Hewitt is a clinician-scientist who leads a group investigating the molecular mechanisms of blinding eye diseases.
His group applies cutting edge, leading biotechnology and bioinformatics solutions to better understand and treat these diseases.
Dr Stuart Keel
BOrth (Hons), PhD
Dr Stuart Keel is devoted to clinical and epidemiological research, with a particular focus on diabetic eye disease.
At CERA, Dr Keel co-managed the first National Eye Health Survey – a population-based study into the prevalence and causes of vision impairment and blindness in non-Indigenous and Indigenous Australians.
He is currently on secondment to the World Health Organization in Geneva where he has made major contributions to the first World Report on Blindness and global eye health policy development.
Dr Nathan Kerr
MBChB, MD, FRANZCO
Dr Nathan Kerr is motivated to help people with glaucoma save their sight by finding better treatments utilising new methods of medication delivery and microscopic devices,
Dr Kerr is investigating a new implant that may replace daily eye drops as well as safer surgical procedures to treat glaucoma.
Dr Isabel Lopez Sanchez
Dr Isabel Lopez Sanchez’ work investigates the mechanisms that regulate mitochondrial biology and how mitochondrial dysfunction can result in neurodegeneration.
She is currently supported by a Mito Foundation Fellowship (2020-2022) to investigate the protective pathways that prevent vision loss in Leber’s Hereditary Optic Neuropathy. She also conducted postdoctoral work at Karolinska Institute, Sweden as a Wenner-Gren Foundation Fellow in 2019.
Associate Professor Lyndell Lim
MBBS, DMedSci, FRANZCO
Associate Professor Lyndell Lim, a uveitis and medical retina subspecialist, leads the Clinical Trials Research at CERA.
Associate Professor Lim’s main research interests are clinical studies in the field of uveitis and ocular immunology, and diabetic retinopathy. Her team runs both investigator-initiated and sponsored clinical trials that aim to investigate new treatments in a variety of ophthalmic disease.
Associate Professor Chi Luu
BOrth(Hons), GradDip(Epi&Biostats), PhD
Associate Professor Chi Luu is Deputy Head of the Macular Research Unit.
He conducts clinical and preclinical research to better understand the pathophysiology of age-related macular degeneration, and to evaluate safety and efficacy of new interventions.
He also investigates novel approaches for vision restoration and neuroprotection of retinal cells, which have the potential to maintain or restore high resolution and colour vision for people with inherited retinal degenerative conditions.
Professor Keith Martin
MA BM BCh DM MRCP FRCOphth FRANZCO ALCM
Professor Keith Martin is Managing Director of the Centre for Eye Research Australia and Ringland Anderson Professor and Head of Ophthalmology at the University of Melbourne.
Professor Martin is working to develop new treatments for eye disease using stem cells, gene therapy and other techniques.
He is co-founder of Quethera, a Cambridge-based gene therapy company which has developed a gene therapy for glaucoma that is currently progressing towards human clinical trials. His other current main research interest is in the potential for regeneration and repair of nerve damage in the eye and brain.
Associate Professor Ian Trounce
Associate Professor Ian Trounce is Principal Investigator and Head of Mitochondria and Neurodegeneration research.
His research focus is on mitochondria and how defects in oxidative phosphorylation contribute to age-related neurodegenerative diseases, including diseases of the optic nerve. His expertise encompasses biochemical, molecular and cell biology and genetic approaches.
Associate Professor Trounce supervises a research team investigating the cellular processes related to ageing and mitochondrial dysfunction that affect the vulnerability of retinal ganglion cells to injury.
Associate Professor Peter van Wijngaarden
MBBS, PhD, FRANZCO
Associate Professor Peter van Wijngaarden is a Deputy Director at CERA. His research focuses on two key areas: novel imaging technologies to detect early markers of eye and central nervous system diseases and research relating to diabetic retinopathy screening uptake and effectiveness.
He is a Clinical Director and a founding member of KeepSight– a Commonwealth Government-funded national approach to diabetic retinopathy screening in Australia.
Dr Raymond C.B. Wong
B.Biomed Sci (Hons), PhD
Dr Raymond CB Wong is a stem cell biologist with 16 years of research experience, specialising in cellular reprogramming, pluripotent stem cells and neural/retinal differentiation.
Dr Wong established the Cellular Reprogramming Unit at CERA with the support of a MAWA Fellowship and a NHMRC New Investigator Project Grant.
Currently, Dr Wong’s research focuses on understanding the genetic signals that define retinal cells, and using cell reprogramming and stem cell technologies to study and treat retinal diseases.